Section Arrow
ACON.NASDAQ
- Aclarion
(Financial Status)
Quotes are at least 15-min delayed:2024/05/12 11:16 EDT
Last
 0.2766
-0.0232 (-7.74%)
Day High 
0.305 
Prev. Close
0.2998 
1-M High
0.69 
Volume 
390.31K 
Bid
0.2766
Ask
0.289
Day Low
0.2706 
Open
0.3035 
1-M Low
0.2706 
Market Cap 
2.14M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.3 
20-SMA 0.3 
50-SMA 0.33 
52-W High 25.6 
52-W Low 0.2668 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-705.60/--
Enterprise Value
2.14M
Balance Sheet
Book Value Per Share
-0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
75.40K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PGNYProgyny27.53-4.97-15.29%52.42PE
MPLNMultiPlan Corp0.7062-0.0148-2.05%-- 
TDOCTeladoc Health11.95-0.29-2.37%-- 
EVHEvolent Health24.46-2.5-9.27%-- 
SHCRSharecare0.7718+0.0884+12.94%-- 
Quotes are at least 15-min delayed:2024/05/12 11:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generatedfrom contracts with customers in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.